CHMP5 and COVID-19: We adjusted the model parameters using anti-Spike antibody data from individuals immunized with the COVID-19 vaccine AstraZeneca, from two sets of data, namely i) the “Vaxab dataset”, a retrospective observational study on anti-RBD-Spike total antibodies in individuals vaccinated against COVID-19 in Naples, Italy, and ii) published serological data from the COV001 and COV002 trials (11).